Akanda

Akanda EPS Growth

The EPS Growth of Akanda (AKAN) as of Oct 30, 2026 is 26.42 %. In the previous year, EPS Growth was 90.19 % — a change of -70.71% (lower).

EPS Growth

26.42 %

YoY

-70.71%

Last updated:

EPS Growth of Akanda is 2025 26.42 % . EPS Growth of Akanda was 2024 90.19 % . It decreases by -70.71% lower compared to the previous year.

The Akanda EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2020
-21.82 USD
Jan 1, 2021
99.78 USD
Jan 1, 2022
-6.91 M USD
Jan 1, 2023
92.62 USD
Jan 1, 2024
90.19 USD
Jan 1, 2025
26.42 USD
The Akanda EPS Growth history
YEAREPS GrowthYoY
26.42 %-70.71%
90.19 %-2.62%
92.62 %-100.00%
-6.91 M %-6.92 M%
99.78 %-557.21%
-21.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

EPS Growth of Akanda is 26.42 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Akanda since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Akanda historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Akanda

All Key Metrics — Akanda